Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

NCT03924895 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

595

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Cancer, Muscle-invasive

Interventions

DRUG: Pembrolizumab
PROCEDURE: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
DRUG: Enfortumab Vedotin

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]
[object Object]